NCT06536049 2026-02-19
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1/2 Recruiting
Clinical Trials
3 trialsNCT07098364 2026-01-14
ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
Fred Hutchinson Cancer Center
Phase 1/2 Recruiting
NCT06249191 2025-03-24
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
OHSU Knight Cancer Institute
Phase 1/2 Recruiting